AWAnwen S. Williams

Anwen S. Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anwen S. Williams has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Table S1 from Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction

    by Emily J. Colbeck, Emma Jones, James P. Hindley, Kathryn Smart, Ralph Schulz, Molly Browne, Scott Cutting, Anwen Williams, Lee Parry, Andrew Godkin, et al.

  • Open Access

    Supplementary Data from Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction

    by Emily J. Colbeck, Emma Jones, James P. Hindley, Kathryn Smart, Ralph Schulz, Molly Browne, Scott Cutting, Anwen Williams, Lee Parry, Andrew Godkin, et al.

  • Open Access

    Peripheral regulatory CD8 + CD28 − KLRG1 + T cells as markers of disease and treatment response in rheumatoid arthritis

    by Charlotte Thompson, Richard Beatson, Ruth Davies, Claire Greenhill, Simon A. Jones, Anwen S. Williams, Gareth W. Jones, Ernest Hs Choy

    Objective: CD3 + CD8 + CD28 − cells are increased in the periphery and tissues of rheumatoid arthritis (RA) patients. The aim of this study was to characterise CD3 + CD8 + CD28 − cells for the presence of cell surface receptors that regulate immune activation and function and to track their presence in a disease model of RA. Cell surface receptors expressed by CD3 + CD8 + CD28 − cells were then related to serological and clinical disease parameters to establish whether these cells are prognostic of a clinical response to conventional DMARDs. Method: Using healthy donor peripheral blood mononuclear (PBMC) cell surface expression of > 50 candidate markers were tested using flow cytometry and compared against CD28 expression. The prevalence of cells expressing the most suitable candidate was investigated in the collagen induced arthritis (CIA) and the antigen-induced arthritis (AIA) models. Fifty RA patients were recruited from University Hospital of Wales (UHW) rheumatology outpatient clinic. Clinical and serological markers of inflammation were noted, and PBMC were analysed using flow cytometry +/− in vitro stimulation. Results: CD3 + CD8 + CD28 − T cells express CD244, CD57, CX3CR1 and KLRG1. The strongest inverse correlate of CD28 expression was KLRG1. CD3 + CD8 + CD28 − KLRG1 + cells were elevated in experimental models of RA. Notably, Il-10-deficiency was linked with exacerbated arthritis and an increase in the number of CD3 + CD8 + CD28 − KLRG1 + cells, suggesting a regulatory role for Il-10 in their development or survival. In RA patients, CD3 + CD8 + CD28 − KLRG1 + cells correlate with ACPA, RF and ESR, and produce more IL-10 than controls. Finally, these cells are higher in early arthritis patients that do not respond to treatment with synthetic DMARDs at six months. Conclusion: KLRG1 is a marker for regulatory CD3 + CD8 + CD28 − cells. The presence of CD3 + CD8 + CD28-KLRG1 + cells increases with certain measures of disease, and is indicative of poor treatment response to DMARDs in early arthritis. Key Messages: KLRG1 is a marker of CD28 negativity on CD8 T cells CD3 + CD8 + CD28 − KLRG1 + cells are increased in CIA mice and correlate with disease severity. CD3 + CD8 + CD28 − KLRG1 + cells positively correlate with ESR / ACPA and RF in patients. CD3 + CD8 + CD28 − KLRG1 + cells are increased in Il-10-deficient mice with inflammatory arthritis. CD3 + CD8 + CD28 − KLRG1 + cells produce more Il-10 than CD3 + CD8 + CD28 + KLRG1 − cells in RA patients. CD3 + CD8 + CD28 − KLRG1 + cells are higher in patients who do not respond to treatment with synthetic DMARDs after six months.


  • Open Access

    AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis

    by Cleo S. Bonnet, Sophie J. Gilbert, Emma J. Blain, Anwen S. Williams, Deborah J. Mason

    Musculoskeletal disorders represent the third greatest burden in terms of death and disability in the developed world. Osteoarthritis is the single greatest cause of chronic pain, has no cure, and affects 8.5 and 27 million people in the UK and US, respectively. Osteoarthritis is most prevalent in older people, but as it commonly occurs after joint injury, young people with such injuries are also susceptible. Painful joints are often treated with steroid or hyaluronic acid (HA) injections, but treatments to prevent subsequent joint degeneration remain elusive. In animals, joint injury increases glutamate release into the joint, acting on nerves to cause pain, and joint tissues to cause inflammation and degeneration. This study investigated synovial fluid glutamate concentrations and glutamate receptor (GluR) expression in injured human joints and compared the efficacy of GluR antagonists with current treatments in a mouse model of injury-induced osteoarthritis (ACL rupture). GluRs were expressed in the ligaments and meniscus after knee injury, and synovial fluid glutamate concentrations ranged from 19 to 129 μM. Intra-articular injection of NBQX (GluR antagonist) at the time of injury substantially reduced swelling and degeneration in the mouse ACL rupture model. HA had no effect, and Depo-Medrone reduced swelling for 1 day but increased degeneration by 50%. Intra-articular administration of NBQX modified both symptoms and disease to a greater extent than current treatments. There is an opportunity for repurposing related drugs, developed for CNS disorders and with proven safety in humans, to prevent injury-induced osteoarthritis. This could quickly reduce the substantial burden associated with osteoarthritis.


  • Open Access

    Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels

    by Fraser L. Collins, Michael D. Stone, Jane Turton, Laura R. McCabe, Eddie C. Y. Wang, Anwen S. Williams

    Oestrogen-deficiency induced by menopause is associated with reduced bone density and primary osteoporosis, resulting in an increased risk of fracture. While the exact etiology of menopause-induced primary osteoporotic bone loss is not fully known, members of the tumour necrosis factor super family (TNFSF) are known to play a role. Recent studies have revealed that the TNFSF members death receptor 3 (DR3) and one of its ligands, TNF-like protein 1A (TL1A) have a key role in secondary osteoporosis; enhancing CD14+ peripheral blood mononuclear cell (PBMC) osteoclast formation and bone resorption. Whether DR3 and TL1A contribute towards bone loss in menopause-induced primary osteoporosis however, remains unknown. To investigate this we performed flow cytometry analysis of DR3 expression on CD14+ PBMCs isolated from pre- and early post-menopausal females and late post-menopausal osteoporotic patients. Serum levels of TL1A, CCL3 and total MMP-9 were measured by ELISA. In vitro osteoclast differentiation assays were performed to determine CD14+ monocyte osteoclastogenic potential. In addition, splenic CD4+ T cell DR3 expression was investigated 1 week and 8 weeks post-surgery, using the murine ovariectomy model. In contrast to pre-menopausal females, CD14+ monocytes isolated from post-menopausal females were unable to induce DR3 expression. Serum TL1A levels were decreased approx. 2-fold in early post-menopausal females compared to pre-menopausal controls and post-menopausal osteoporotic females; no difference was observed between pre-menopausal and late post-menopausal osteoporotic females. Analysis of in vitro CD14+ monocyte osteoclastogenic potential revealed no significant difference between the post-menopausal and post-menopausal osteoporotic cohorts. Interestingly, in the murine ovariectomy model splenic CD4+ T cell DR3 expression was significantly increased at 1 week but not 8 weeks post-surgery when compared to the sham control. Our results reveals for the first time that loss of oestrogen has a significant effect on DR3; decreasing expression on CD14+ monocytes and increasing expression on CD4+ T cells. These data suggest that while oestrogen-deficiency induced changes in DR3 expression do not affect late post-menopausal bone loss they could potentially have an indirect role in early menopausal bone loss through the modulation of T cell activity.


  • Open Access

    Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis

    by Lauren A Jordan, Malin C Erlandsson, Benjamin F Fenner, Ruth Davies, Ann K Harvey, Ernest H Choy, Rachel Errington, Maria I Bokarewa, Anwen S Williams

    Macrophage inflammatory protein 1-alpha (CCL3) is a chemokine that regulates macrophage trafficking to the inflamed joint. The agonistic effect of CCL3 on osteolytic lesions in patients with multiple myeloma is recognized; however, its role in skeletal damage during inflammatory arthritis has not been established. The aim of the study was to explore the role of osteoclast-associated CCL3 upon bone resorption, and to test its pharmacological blockade for protecting against bone pathology during inflammatory arthritis. CCL3 production was studied during osteoclast differentiation from osteoclast precursor cells: human CD14-positive mononuclear cells. Mice with CIA were treated with an anti-CCL3 antibody. The effect of CCL3 blockade through mAb was studied through osteoclast number, cytokine production and bone resorption on ivory disks, and in vivo through CIA progression (clinical score, paw diameter, synovial inflammation and bone damage). Over time, CCL3 increased in parallel with the number of osteoclasts in culture. Anti-CCL3 treatment achieved a concentration-dependent inhibition of osteoclast fusion and reduced pit formation on ivory disks (P ⩽ 0.05). In CIA, anti-CCL3 treatment reduced joint damage and significantly decreased multinucleated tartrate-resistant acid phosphatase-positive osteoclasts and erosions in the wrists (P < 0.05) and elbows (P < 0.05), while also reducing joint erosions in the hind (P < 0.01) and fore paws (P < 0.01) as confirmed by X-ray. Inhibition of osteoclast-associated CCL3 reduced osteoclast formation and function whilst attenuating arthritis-associated bone loss and controlling development of erosion in murine joints, thus uncoupling bone damage from inflammation. Our findings may help future innovations for the diagnosis and treatment of inflammatory arthritis.


  • Open Access

    257 IL-6 trans-signaling causes accelerated atherosclerosis in disease-prone animals

    by Ruth Davies, Hyun-Sun Jin, Jessica O Williams, Katie Sime, Keith Allen-Redpath, Charlotte Thompson, Gareth Jones, Simon Jones, Timothy Hughes, Stefan Rose-John, et al.

    Background: Cardiovascular (CV) disease is a major cause of mortality in patients with rheumatoid arthritis (RA). CV risk is increased early in the disease course. Subclinical inflammation and dyslipidaemia can often be seen in RA before patients become symptomatic, suggesting the presence of subclinical CV disease. Inflammation, as measured by acute phase reactants, is associated with CV disease in RA. Interleukin (IL)-6 is a major driver of the acute phase response in RA. Notably, systemic elevations in inflammatory cytokines including IL-6 correlate with CV risk. Importantly, IL-6 regulates both immune homeostasis and inflammatory processes linked with chronic disease progression. Control of these processes is regulated by two modes of IL-6 signaling; classical IL-6 receptor signaling and IL-6 trans-signaling. Cellular responses controlled by IL-6 trans-signaling are mediated via soluble IL-6 receptor (sIL-6R) and is widely considered to promote deleterious pro-inflammatory outcomes. We hypothesise that atherosclerosis may predate diagnosis of RA, and is accelerated by IL-6 trans-signaling during active arthritis. Here, we investigate this hypothesis using the established ApoE-deficient (apoE-/-) mouse model of atherosclerosis. Objective: To examine the effect of IL-6 classical and trans-signaling on atherosclerosis by administering IL-6 or Hyper-IL-6 (an IL-6: sIL-6R fusion protein) to apoE-/- mice.


  • Open Access

    CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss

    by Fraser L. Collins, Jessica O. Williams, Anja C. Bloom, Ravinder K. Singh, Lauren Jordan, Michael D. Stone, Laura R. McCabe, Eddie C.Y. Wang, Anwen S. Williams


  • Open Access

    Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice

    by Katie Sime, Ernest H. Choy, Anwen S. Williams

    The physiologic function of adipose tissue is altered by the host's inflammatory response; the implications for maintaining human health and regulating inflammation-associated disease progression are ill defined. However, this cannot be investigated in humans, therefore the use of animal models is required. With the aim to determine morphological and molecular alterations to perivascular and organ-associated adipose tissues during inflammatory arthritis, collagen-induced arthritis (CIA) was established in male DBA/1 mice. Emerging evidence from this study signposts CIA in the DBA/1 mouse as a model that is relevant to study the development and treatment of early cardiovascular pathology associated with inflammatory arthritis. Here, we show global morphological changes in adipose tissue and the thoracic aorta in animals induced with CIA compared with the non-immunized controls. In CIA, we concluded that the increased cell count in PVAT was, at least in part, caused by an ingress and/or expansion of macrophages that had a mixed phenotype. A substantial increase of galectin-3 was expressed in PVAT from mice with CIA. Galectin-3 is elevated in the blood of patients with CVDs, however, it has never before been measured in PVAT in rodents or humans. Here, PVAT-associated galectin-3 is identified as a potential biomarker for detecting early vascular pathology in CIA and a promising candidate for translation to RA.


  • Open Access

    Review: Novel Insights Into Tumor Necrosis Factor Receptor, Death Receptor 3, and Progranulin Pathways in Arthritis and Bone Remodeling

    by Anwen Williams, Eddie C. Y. Wang, Lorenz Thurner, Chuan‐Ju Liu